Abstract:Jie Xie, &ast Xu Xiao, &ast Zhenjia Dong, Qiangdong Wang Department of Urology, the Fifth People's Hospital of Huai'an, Huai'an City, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qiangdong Wang, Email Background: The systemic inflammation score (SIS) based on the albumin (Alb) level and lymphocyte-to-monocyte ratio (LMR), has been associated with survival in some cancers. However, its prognostic role in prostate cancer (PCa) remains unclear. Methods: The associations between the SIS and the clinicopathological features of PCa were evaluated. The correlations between the SIS and overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis and the Log rank test. Univariate and multivariate Cox analyses were conducted to determine the prognostic factors for PCa. Hazard ratios and 95% confidence intervals were calculated. Results: A total of 253 patients with PCa were included in this study. The Kaplan-Meier analysis and Log rank test suggested that patients with a higher Alb level, higher LMR, or a lower SIS had better 5-year OS and PFS compared with patients with a lower Alb level or lower LMR or higher SIS. Univariate and multivariate Cox analyses showed that drinking, prostate-specific antigen level > 100 ng/mL, and neutrophil-to-lymphocyte ratio > 2.09 were significant prognostic factors for OS and PFS in patients with PCa. Nomograms for 5-year OS and PFS were established with concordance index values of 0.888 and 0.824, respectively. The calibration curve was consistent between the actual observations and the prediction nomogram for OS and PFS probability at 5 years. Conclusion: A high SIS is associated with unfavorable survival in patients with PCa. The SIS serves as a novel independent prognostic factor for OS in patients with PCa. Keywords: systemic inflammation score, prostate cancer, progression-free survival, overall survival Prostate cancer (PCa) is a malignant tumor that occurs in males and affects millions of patients globally. 1 PCa has the fourth highest incidence of all cancers worldwide. 2 Prostate biopsies, imaging, and biomarkers are used to diagnose PCa. 3 Approximately 1.3 million new PCa cases are diagnosed worldwide annually. 4 Approximately 10 million people are currently diagnosed with PCa, of which approximately 700,000 have metastatic disease. 5,6 Despite substantial advances in treatment for PCa, the prognosis of metastatic PCa is frustrating. 7 Thus, novel prognostic biomarkers are needed to identify PCa patients with a higher probability of an adverse prognosis and to help to make an appropriate treatment plan. Persistent chronic inflammation increases cancer risk and promotes the formation of tumors. 8,9 Tumor-associated inflammation initiates tumorigenesis and drives malignant progression. 10,11 A host of hematological inflammatory biomarkers, including the albumin (Alb) level, neutrophil, lymphocyte, and monocyte counts, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and platelet-to-lymphocyte ratio (PLR) are predictive markers in cancer patients. 12–18 Tests for these biomarkers are available in routine clinical practice and help clinicians evaluate the clinical outcomes and survival of cancer patients. A new marker, called the systemic inflammation score (SIS), which is based on the Alb level and LMR, has been proposed. 19 The SIS reflects nutrition and inflammation status, which was significantly associated with the clinical outcomes and prognosis of cancer. 20–22 The preoperative SIS was shown to be an effective prognostic factor in many cancers. 19,23–26 However, studies on the ability of the SIS system to predict the survival of PCa patients have not been reported. Thus, in this study, we elucidated the prognostic effect of the pretherapeutic SIS in patients with PCa in a Chinese Han population. In total, 253 patients with PCa were recruited from our hospital between January 2016 and December 2018. Inclusion criteria were as follows: 1. PCa patients came from Jiangsu province; 2. PCa was diagnosed by histology; 3. the survival time was more than one year. Exclusion criteria were as follows: 1. patients who received chemotherapy; 2. patients without complete laboratory parameters; 3. patients who was lost to follow-up; 4. patients with immunodeficiency diseases. Clinicopathological parameters for patients with PCa were collected from medical records. The blood test data were taken at the time of the initial visit before the biopsy. Informed consent was provided by all participants. This study was approved by -Abstract Truncated-

Prognostic Significance of the Presence of Intraductal Carcinoma of the Prostate and Bone Metastasis in Needle Biopsy for Prostate Carcinoma Patients with Grade Group 5.

Sites of Synchronous Distant Metastases and Prognosis in Prostate Cancer Patients with Bone Metastases at Initial Diagnosis: a Population-Based Study of 16,643 Patients.

Prognosis of Prostate Cancer and Bone Metastasis Pattern of Patients: a SEER-based Study and a Local Hospital Based Study from China

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Prognostic Values of Clinicopathological Characteristics and Survival Outcomes in Prostate Infiltrating Ductal Carcinoma: a Population-Based Study

Identification of biomarkers associated with pathological tumor staging and their utility in the diagnosis and prognosis of prostate cancer

Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients

The presence of intraductal carcinoma of prostate is a risk factor for poor pathologic response in men with high-risk prostate cancer receiving neoadjuvant therapy

Clinicopathological Features, Prognostic Factors and Survival in Patients With Pancreatic Cancer Bone Metastasis

The Systemic Inflammation Score is Associated with the Survival of Patients with Prostate Cancer

Clinical features and prognostic factors for patients with bone metastases from prostate cancer.

Intraductal Prostate Cancer Affinity for Lymphatic-Predominant Metastases Through 18 F-DCFPyL‒Prostate-Specific Membrane Antigen‒Positron Emission Tomography/CT Scans in Pretreatment Prostate Cancer Patients

Integrated machine learning algorithms reveal a bone metastasis-related signature of circulating tumor cells in prostate cancer

Prognostic Significance of Young Age and Non-Bone Metastasis at Diagnosis in Patients with Metastatic Prostate Cancer: a SEER Population-Based Data Analysis

Prognostic Value of Her-2/neu and Clinicopathologic Factors for Evaluating Progression and Disease-Specific Death in Chinese Men with Prostate Cancer

Assessing the predictive value of intraductal carcinoma of the prostate (IDC‐P) in determining abiraterone efficacy for metastatic hormone‐sensitive prostate cancer (mHSPC) patients

When to perform bone scintigraphy in patients with newly diagnosed prostate cancer? a retrospective study

Pretreatment level of serum sialic acid predicts both qualitative and quantitative bone metastases of prostate cancer

Association of initial prostate specific antigen level in prostate cancer patients with bone metastasis with cancer-specific survival

Prognosis of Men with High-Risk Prostate Cancer Stratified by Risk Factors: a Population-Based Retrospective Cohort Study.